TY - JOUR
T1 - Development of a β-HPV vaccine
T2 - Updates on an emerging frontier of skin cancer prevention
AU - Gupta, Rohit
AU - Rady, Peter L.
AU - Doan, Hung Q.
AU - Tyring, Stephen K.
N1 - Publisher Copyright:
© 2020 Elsevier B.V.
PY - 2020/5
Y1 - 2020/5
N2 - Human papillomaviruses (HPVs) are small, non-enveloped, doublestranded DNA viruses. Over 200 subtypes of HPV have been identified, organized into five major genera. β-HPVs are a group of approximately 50 HPV subtypes that preferentially infect cutaneous sites. While α-HPVs are primarily responsible for genital lesions and mucosal cancers, growing evidence has established an association between β-HPVs and the development of cutaneous squamous cell carcinomas. Given this association, the development of a vaccine against β-HPVs has become an important topic of research; however, currently licensed vaccines only provide coverage for genital HPVs, leaving β-HPV infections and their associated skin cancers unaddressed. In this review, we summarize the current advances in β-HPV vaccine development, including progress made in preclinical testing and limited clinical data. We also discuss novel findings in the viral pathomechanisms involved in β-HPV cutaneous tumorigenesis that may play a large role in future vaccine development. We hope that synthesizing the available data and advances surrounding β- HPV vaccine development will not only lead to increased dedication to vaccine development, but also heightened awareness of a future vaccine among clinicians and the public.
AB - Human papillomaviruses (HPVs) are small, non-enveloped, doublestranded DNA viruses. Over 200 subtypes of HPV have been identified, organized into five major genera. β-HPVs are a group of approximately 50 HPV subtypes that preferentially infect cutaneous sites. While α-HPVs are primarily responsible for genital lesions and mucosal cancers, growing evidence has established an association between β-HPVs and the development of cutaneous squamous cell carcinomas. Given this association, the development of a vaccine against β-HPVs has become an important topic of research; however, currently licensed vaccines only provide coverage for genital HPVs, leaving β-HPV infections and their associated skin cancers unaddressed. In this review, we summarize the current advances in β-HPV vaccine development, including progress made in preclinical testing and limited clinical data. We also discuss novel findings in the viral pathomechanisms involved in β-HPV cutaneous tumorigenesis that may play a large role in future vaccine development. We hope that synthesizing the available data and advances surrounding β- HPV vaccine development will not only lead to increased dedication to vaccine development, but also heightened awareness of a future vaccine among clinicians and the public.
KW - Cutaneous squamous cell carcinoma
KW - Humanpapilloma virus
KW - Skin cancer prevention
KW - Vaccine
KW - β-HPV
UR - http://www.scopus.com/inward/record.url?scp=85083384503&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083384503&partnerID=8YFLogxK
U2 - 10.1016/j.jcv.2020.104348
DO - 10.1016/j.jcv.2020.104348
M3 - Review article
C2 - 32334327
AN - SCOPUS:85083384503
SN - 1386-6532
VL - 126
JO - Journal of Clinical Virology
JF - Journal of Clinical Virology
M1 - 104348
ER -